公开(公告)号：EP1711507A1

公开(公告)日：2006-10-18

申请号：EP05700509.2

申请日：2005-02-04

申请人： Zentiva, a.s.

发明人： RICHTER, Jindrich ,  JIRMAN, Josef

IPC分类号： C07F9/58 ,  A61K31/663 ,  A61P19/00

CPC分类号： C07F9/582

摘要： Crystalline monosodium salt of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid, having the X-ray pattern with characteristic interplanar distances 4.35; 8.44; 13.42 and 15.73 ú.

公开(公告)号：EP1653930A2

公开(公告)日：2006-05-10

申请号：EP04738465.6

申请日：2004-08-05

申请人： Zentiva, a.s.

发明人： SEBEK, Pavel ,  PROKOPOVA, Alena ,  SVOBODA, Eduard ,  RADL, Stanislav ,  STACH, Jan ,  SVOBODA, Martin ,  KOVACIK, Andrej ,  DANKO, Adrian ,  PETRO, Roman ,  STRIZINEC, Miroslav

IPC分类号： A61K9/20 ,  A61K31/40

CPC分类号： A61K31/40 ,  A61K9/2054 ,  A61K9/2866

摘要： Stabilization of the pharmaceutical active solid substance atorvastatin alone or in a mixture with other solid substances embedded in a gaseous mixture is carried out in such a manner that in the surrounding gaseous mixture a partial pressure of oxygen of at most 2 kPa, preferably less than 1 kPa, more preferably less than 0.4 kPa is maintained. The corresponding partial pressure is achieved either by use of oxygen absorbers, by packaging under a pressure of 0.3 - 10 kPa, or by packaging under a slight overpressure of an inert gas, preferably nitrogen, the gas being introduced, by means of nozzles, into the cavities, optionally also into the space of the press roller and of the wiper station.

公开(公告)号：EP2029587B1

公开(公告)日：2015-09-02

申请号：EP07764312.0

申请日：2007-06-21

申请人： Zentiva, a.s.

发明人： JIRMAN, Josef ,  JUNEK, Richard ,  LUSTIG, Petr ,  RICHTER, Jindrich ,  PLACEK, Lukas

IPC分类号： C07D453/02

CPC分类号： C07D453/02

公开(公告)号：EP2832723A1

公开(公告)日：2015-02-04

申请号：EP13003774.0

申请日：2013-07-29

申请人： Zentiva, a.s.

发明人： Davis, Dita ,  Ridvan, Ludek ,  Stepankova, Hana ,  Sedmak, Gregor

IPC分类号： C07D209/52 ,  A61K9/10

CPC分类号： C07D209/52 ,  A61K9/1635 ,  A61K9/1652 ,  A61K31/403

摘要： Glass solution or glass suspension of saxagliptin base, or pharmaceutically acceptable salt thereof, dispersed within a polymer matrix, wherein the polymer is selected from polyvinylpyrrolidone, hydroxypropyl methylcellulose and hydroxypropylcellulose.

摘要翻译： 分散在聚合物基质内的沙格列汀碱或其药学上可接受的盐的玻璃溶液或玻璃悬浮液，其中聚合物选自聚乙烯吡咯烷酮，羟丙基甲基纤维素和羟丙基纤维素。

公开(公告)号：EP2813216A1

公开(公告)日：2014-12-17

申请号：EP13002963.0

申请日：2013-06-10

申请人： Zentiva, a.s.

发明人： Davis, Dita ,  Sedmak, Gregor ,  Ridvan, Ludek ,  Kral, Vladimir

IPC分类号： A61K9/14 ,  A61K9/16 ,  A61K31/00

CPC分类号： A61K9/146 ,  A61K9/1611 ,  A61K9/1635 ,  A61K9/1641 ,  A61K9/1652 ,  A61K31/519

摘要： Solid solution of ticagrelor molecularly dispersed within a polymer matrix formed by an ionic polymer in its solid state, characterized in that the ionic polymer is selected from hydroxypropyl methyl cellulose, polyvinylpyrrolidone or polyvinyl caprolactam-polyvinyl acetate-polyethyleneglycol.

摘要翻译： 泰格列洛的固体溶液分散分散在由固体状态的离子聚合物形成的聚合物基质中，其特征在于离子聚合物选自羟丙基甲基纤维素，聚乙烯吡咯烷酮或聚乙烯基己内酰胺 - 聚乙酸乙烯酯 - 聚乙二醇。

公开(公告)号：EP2810647A1

公开(公告)日：2014-12-10

申请号：EP13002931.7

申请日：2013-06-06

申请人： Zentiva, a.s.

发明人： Rezac, Jaroslav ,  Novak, Martin ,  Pribyl, Daniel ,  Hanovska, Anna ,  Ridvan, Ludek ,  Dumicic, Aleksandra ,  Kral, Vladimir

IPC分类号： A61K31/165 ,  A61K47/12 ,  A61P25/20 ,  A61P25/22 ,  A61P25/24

CPC分类号： A61K9/20 ,  A61K31/165 ,  C07C57/145 ,  C07C59/265

摘要： A pharmaceutical formulation, comprising agomelatine in the form of agamelatine co-crystal with a co-crystal former selected from the group of organic acids in an amount corresponding to 15 - 22 mg agomelatitte dose per one dosage unit and at least one pharmaceutically acceptable excipient for effective treatment of diseases responsive to therapy by agomelatine.

摘要翻译： 的药物制剂，在对应于每一个剂量单位和至少一种药学上可接受的赋形剂为15-22毫克agomelatitte剂量的量在选自有机酸选择agamelatine共晶体具有共晶前的形式，其包括阿戈美拉汀 有效的治疗的响应于治疗的疾病由阿戈美拉汀。

公开(公告)号：EP1879565A2

公开(公告)日：2008-01-23

申请号：EP06705758.8

申请日：2006-04-06

申请人： Zentiva, a.s.

发明人： FORTOVA, Jitka ,  MRVOVA, Zdenka ,  KRISTENOVA, Pavlina

IPC分类号： A61K31/18 ,  A61K9/06 ,  A61K47/10 ,  A61K47/26 ,  A61P29/00

CPC分类号： A61K9/0014 ,  A61K31/18 ,  A61K47/10 ,  A61K47/14 ,  A61K47/26

摘要： The topical pharmaceutical formulation containing nimesulide contains a hydration agent, preferably propyleneglycol, a non-ionic surface-active substance and optionally other pharmaceutically acceptable additives.

公开(公告)号：EP1771444B1

公开(公告)日：2007-11-21

申请号：EP05759059.8

申请日：2005-07-20

申请人： Zentiva, a.s.

发明人： HALAMA, Ales

IPC分类号： C07D417/12 ,  A61K31/4402 ,  A61P3/10

CPC分类号： C07D417/12

摘要： The salt of oxalic acid with 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)-ethoxy]-benzyl]-thiazolidin-2,4-dione of formula III including its tautomers and solvates. The method of preparation of the salt of oxalic acid with 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)-ethoxy]benzyl]thiazolidin-2,4-dione consists in a reaction of 5-[4-[2-(N-methyl-N-(2-pyridyl)-amino)ethoxy]benzyl]thiazolidin-2,4-dione of formula I with oxalic acid, the reaction being carried out in a solution in organic solvent or its mixture with water.

摘要翻译： 草酸盐与式III的5- [4- [2-（N-甲基-N-（2-吡啶基）氨基] - 乙氧基] - 苄基] - 噻唑烷-2,4-二酮（包括其互变异构体和溶剂化物 。 用5- [4- [2-（N-甲基-N-（2-吡啶基）氨基] - 乙氧基]苄基]噻唑烷-2,4-二酮制备草酸盐的方法包括 式I的5- [4- [2-（N-甲基-N-（2-吡啶基） - 氨基）乙氧基]苄基]噻唑烷-2,4-二酮与草酸反应，该反应在 有机溶剂或其与水的混合物。

公开(公告)号：EP1556041B1

公开(公告)日：2007-08-29

申请号：EP03757655.0

申请日：2003-10-21

申请人： Zentiva, a.s.

发明人： RICHTER, Jindrich ,  JIRMAN, Josef

IPC分类号： A61K31/4406 ,  A61K31/663 ,  C07F9/38 ,  C07F9/58

CPC分类号： C07F9/582

摘要： A crystalline, hydrated form of the sodium salt of 3-pyridyl-1-hydroxyethylidene-1,l-bisphosphonic acid contains from 6.4 up to 22 weight % of sodium, based on the anhydrous substance, and 15 up to 23 weight % of crystalline water if the sodium content is lower than 7.5 weight %, or 4.5 up to 18 weight % if the sodium content is higher than 7.5 weight %.

公开(公告)号：EP1782833A2

公开(公告)日：2007-05-09

申请号：EP06025316.8

申请日：2002-12-20

申请人： Zentiva, a.s.

发明人： Ulbrich, Karel ,  Etrych, Thomás ,  Rihova, Blanka, ,  Jelinkova, Markéta ,  Kovar, Marek

IPC分类号： A61K47/48

CPC分类号： A61K47/6883 ,  A61K47/65

摘要： Conjugates consisting of a polymeric carrier constituted by 30 to 3,000 monomer units linked to form a polymeric chain, composed of
a. 60 to 99 % of N -(2-hydroxypropyl)methacrylamide units
b. 1 to 25 % of units of methacryloylated hydrazones of α-amino acids, ε-amino acids, aromatic amino acids, or oligopeptides terminated with a molecule of an anthracycline cancerostatic
c. 0.5 to 15 % of units ofmethacryloylated α-amino acids, ε-amino acids, aromatic amino acids or oligopeptides or their sodium salts, and optionally
d. 0.5 to 10 % of units of methacryloylated hydrazides of α-amino acids, ε-amino acids, aromatic amino acids or oligopeptides
e. 0.5 to 5 % of methacryloylated α-amino acids, ε-amino acids or oligopeptides terminated by a molecule of immunoglobulin or of a specific monoclonal or polyclonal antibody,

of the below given general formula, the individual structural units being disposed in a random manner in the chain and where x ranges from 20 to 3,000, a is from 1 to 750, b and c are each from 1 to 450, d ranges from 1 to 150, X is a residue of an amino acid or oligopeptide chosen from the following series: Gly, Ala, Leu, GlyGly, GlyLeuGly, GlyPheGly, GlyPheLeuGly, β-alanine, γ-amino butyric acid, ε-amino caproic acid (AKap), p-amino benzoic acid (AB), and S is an antibody selected from the following series: γ-globulin for i.v. administrations, autologous antibodies, antibodies anti-17-1A, anti-CA 15-3 and the like, linked to the polymeric chain by the marked structure.

摘要翻译： 由聚合物载体组成的共轭体由30至3,000个连接形成聚合物链的单体单元构成，由a。 60-99％的N-（2-羟丙基）甲基丙烯酰胺单元b。 1-氨基酸，μ-氨基酸，芳香族氨基酸或用蒽环类抗癌药物c分子终止的寡肽的甲基丙烯酰化腙单位的1〜25％。 0.5至15％的甲基丙烯酰化±氨基酸，μ-氨基酸，芳族氨基酸或寡肽或其钠盐的单元，以及任选的d。 ±10-氨基酸，μ-氨基酸，芳香族氨基酸或寡肽的甲基丙烯酰化酰肼单位为0.5〜10％ 0.5至5％的由下列给定通式的免疫球蛋白或特异性单克隆或多克隆抗体分子封端的甲基丙烯酰化的± - 氨基酸，μ-氨基酸或寡肽，各个结构单元以随机方式置于 链，其中x为20至3,000，a为1至750，b和c各自为1至450，d的范围为1至150，X为选自以下系列的氨基酸或寡肽的残基 ：Gly，Ala，Leu，GlyGly，GlyLeuGly，GlyPheGly，GlyPheLeuGly，2-丙氨酸，3-氨基丁酸，μ-氨基己酸（AKap），对氨基苯甲酸（AB），S是选自 以下系列：³-球蛋白iv 给药，自体抗体，抗-17-1A抗体，抗CA15-3等抗体，通过标记结构与聚合物链连接。